How country-specific should a country-specific cost-effectiveness analysis be?
Publication
, Journal Article
Reed, SD
Published in: Eur Heart J
January 2013
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
January 2013
Volume
34
Issue
3
Start / End Page
166 / 167
Location
England
Related Subject Headings
- beta-Alanine
- Warfarin
- Ticagrelor
- Platelet Aggregation Inhibitors
- Male
- Humans
- Female
- Dabigatran
- Cardiovascular System & Hematology
- Benzimidazoles
Citation
APA
Chicago
ICMJE
MLA
NLM
Reed, S. D. (2013). How country-specific should a country-specific cost-effectiveness analysis be? Eur Heart J, 34(3), 166–167. https://doi.org/10.1093/eurheartj/ehs204
Reed, Shelby D. “How country-specific should a country-specific cost-effectiveness analysis be?” Eur Heart J 34, no. 3 (January 2013): 166–67. https://doi.org/10.1093/eurheartj/ehs204.
Reed SD. How country-specific should a country-specific cost-effectiveness analysis be? Eur Heart J. 2013 Jan;34(3):166–7.
Reed, Shelby D. “How country-specific should a country-specific cost-effectiveness analysis be?” Eur Heart J, vol. 34, no. 3, Jan. 2013, pp. 166–67. Pubmed, doi:10.1093/eurheartj/ehs204.
Reed SD. How country-specific should a country-specific cost-effectiveness analysis be? Eur Heart J. 2013 Jan;34(3):166–167.
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
January 2013
Volume
34
Issue
3
Start / End Page
166 / 167
Location
England
Related Subject Headings
- beta-Alanine
- Warfarin
- Ticagrelor
- Platelet Aggregation Inhibitors
- Male
- Humans
- Female
- Dabigatran
- Cardiovascular System & Hematology
- Benzimidazoles